Constriction of carotid arteries by urokinase-type plasminogen activator requires catalytic activity and is independent of NH2-terminal domains

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 983-992

  Massey, Philip G ^a   Tanaka, Shinji ^a   Buckler, Joshua M ^a   Jiang, Bo ^a   McCourtie, Anton ^a   Qian, Kun ^a   Tom, Clifford ^b   Stempien Otero, April ^a   Wen, Shan ^a   Luttrell, Ian ^a   Chitaley, Kanchan ^a   Dichek, David A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endothelial cells; Gene therapy; Gene transfer; Proteases; Vascular remodelling

Indexed keywords

UROKINASE;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY WALL; ARTICLE; CAROTID ARTERY; CATALYSIS; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBRINOLYSIS; KRINGLE DOMAIN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANIMALS; CAROTID ARTERY, COMMON; CATALYSIS; CATALYTIC DOMAIN; ENDOTHELIAL CELLS; FIBRINOLYSIS; GENETIC VECTORS; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; MUTAGENESIS, SITE-DIRECTED; MYOCYTES, SMOOTH MUSCLE; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; SPECIFIC PATHOGEN-FREE ORGANISMS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASOCONSTRICTION;

EID: 70449581253     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-03-0161     Document Type: Article

References (44)

1. Padró T, Emeis JJ, Steins M, et al. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995; 15: 893-902.
2. Kienast J, Padro T, Steins M, et al. Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb Haemost 1998; 79: 579-586. (Pubitemid 28120793)
3. Bachmann F. Plasminogen-Plasmin Enzyme System. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Fourth ed. Lippincott, Williams, and Wilkins, Philadelphia; 2001; 275-320.
4. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
5. Verso M, Agnelli G. Prophylaxis of upper limb deep vein thrombosis in cancer patients with central vein catheter. Thromb Haemost 2008; 100: 167-168. (Pubitemid 351948765)
6. Zreiqat H, James B, Brieger D, et al. Acute coronary stent thrombosis: toward insights into possible mechanism using novel imaging methods. Thromb Haemost 2008; 99: 976-977. (Pubitemid 351705324)
7. Haj-Yehia A, Nassar T, Sachais BS, et al. Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo. FASEB J 2000; 14: 1411-1422. (Pubitemid 30439750)
8. Falkenberg M, Tom C, DeYoung MB, et al. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci USA 2002; 99: 10665-10670. (Pubitemid 34907034)
9. Plekhanova O, Berk BC, Bashtrykov P, et al. Oligonucleotide microarrays reveal regulated genes related to inward arterial remodeling induced by urokinase plasminogen activator. J Vasc Res 2008; 46: 177-187.
10. Nassar T, Haj-Yehia A, Akkawi S, et al. Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem 2002; 277: 40499-40504. (Pubitemid 35215627)
11. Adams DS, Griffin LA, Nachajko WR, et al. A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor. J Biol Chem 1991; 266: 8476-8482.
12. Dichek DA, Anderson J, Kelly AB, et al. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996; 93: 301-309. (Pubitemid 26031489)
13. Lijnen HR, Nelles L, Holmes WE, et al. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator. J Biol Chem 1988; 263: 5594-5598. (Pubitemid 18122898)
14. Stump DC, Stassen JM, Demarsin E, et al. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator. Blood 1987; 69: 592-596. (Pubitemid 17022033)
15. Mostov KE, Friedlander M, Blobel G. The receptor for transepithelial transport of IgA and IgM contains multiple immunoglobulin-like domains. Nature 1984; 308: 37-43. (Pubitemid 14130929)
16. Reich V, Mostov K, Aroeti B. The basolateral sorting signal of the polymeric immunoglobulin receptor contains two functional domains. J Cell Sci 1996; 109: 2133-2139. (Pubitemid 26265693)
17. Vines DJ, Lee SW, Dichek DA, et al. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase. J Pept Sci 2000; 6: 432-439.
18. Wen S, Schneider DB, Driscoll RM, et al. Second-generation adenoviral vectors do not prevent rapid loss of transgene expression and vector DNA from the arterial wall. Arterioscler Thromb Vasc Biol 2000; 20: 1452-1458. (Pubitemid 30353873)
19. Bett AJ, Haddara W, Prevec L, et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
20. Ginsberg HS, Lundholm-Beauchamp U, Horswood RL, et al. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci USA 1989; 86: 3823-3827.
21. Lee SW, Trapnell BC, Rade JJ, et al. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993; 73: 797-807.
22. Dichek DA, Lee SW, Nguyen NH. Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors. Blood 1994; 84: 504-516.
23. Estreicher A, Wohlwend A, Belin D, et al. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989; 264: 1180-1189. (Pubitemid 19038109)
24. Schneider DB, Vassalli G, Wen S, et al. Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 2000; 20: 298-308. (Pubitemid 30086084)
25. Lee SW, Kahn ML, Dichek DA. Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation. J Biol Chem 1992; 267: 13020-13027.
26. Langille BL, Bendeck MP, Keeley FW. Adaptations of carotid arteries of young and mature rabbits to reduced carotid blood flow. Am J Physiol 1989; 256: H931-939.
27. Luttrell IP, Swee M, Starcher B, et al. Erectile dysfunction in the type II diabetic db/db mouse: impaired venoocclusion with altered cavernosal vasoreactivity and matrix. Am J Physiol Heart Circ Physiol 2008; 294: H2204-2211.
28. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-12758. (Pubitemid 21907159)
29. Zeiher AM, Drexler H, Wollschlager H, et al. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
30. Drew AF, Tucker HL, Kombrinck KW, et al. Plasminogen is a critical determinant of vascular remodeling in mice. Circ Res 2000; 87: 133-139. (Pubitemid 30616909)
31. Levi M, Moons L, Bouche A, et al. Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation 2001; 103: 2014-2020. (Pubitemid 32322231)
32. Lafont A, Guzman LA, Whitlow PL, et al. Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995; 76: 996-1002.
33. Gulba DC, Bode C, Runge MS, et al. Thrombolytic agents - an overview. Ann Hematol 1996; 73: S9-S27.
34. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993; 87: 38-52.
35. Gorich J, Rilinger N, Sokiranski R, et al. Mechanical thrombolysis of acute occlusion of both the superficial and the deep femoral arteries using a thrombectomy device. AJR Am J Roentgenol 1998; 170: 1177-1180. (Pubitemid 28210922)
36. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208-215.
37. Clowes AW, Clowes MM, Au YPT, et al. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-67.
38. Backstrom JR, Tokes ZA. The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem 1995; 64: 1312-1318.
39. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999; 85: 906-911. (Pubitemid 29534165)
40. Fernandez-Patron C, Stewart KG, Zhang Y, et al. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 2000; 87: 670-676. (Pubitemid 30778314)
41. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 27-36. (Pubitemid 46370476)
42. Akkawi S, Nassar T, Tarshis M, et al. LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol 2006; 291: H1351-1359.
43. Dichek DA, Neville RF, Zwiebel JA, et al. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989; 80: 1347-1353.
44. Santo SD, Tepper OM, von Ballmoos MW, et al. Cell-based therapy facilitates venous thrombus resolution. Thromb Haemost 2009; 101: 460-464.